Association of nucleos(T)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B - A nationwide cohort study

Gastroenterology

Volumn 147, Issue 1, 2014, Pages

  Wu, Chun Ying ^a,b,c,d   Lin, Jaw Town ^e,f,g   Ho, Hsiu J ^e   Su, Chien Wei ^b,h   Lee, Teng Yu ^a,c   Wang, Shen Yung ^b   Wu, Chuhui ^b   Wu, Jaw Ching ^b,h  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^e FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^f E DA HOSPITAL   (Taiwan)

^g NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^h TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Antiviral Agent; HBV; Hepatoma; NHIRD

Indexed keywords

ENTECAVIR; LAMIVUDINE; LIVER PROTECTIVE AGENT; NUCLEOSIDE ANALOG; TELBIVUDINE;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; CANCER RISK; CEREBROVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INCIDENCE; KIDNEY FAILURE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT DURATION;

ANTIVIRAL AGENT; HBV; HEPATOMA; NHIRD;

ADULT; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; HEPATITIS B, CHRONIC; HUMANS; INCIDENCE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NUCLEOSIDES; NUCLEOTIDES; RETROSPECTIVE STUDIES; RISK FACTORS; TAIWAN; TREATMENT OUTCOME;

EID: 84902990516     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2014.03.048     Document Type: Article

References (40)

1. A. Jemal, F. Bray, and M.M. Center et al. Global cancer statistics CA Cancer J Clin 61 2011 69 90
2. H.B. El-Serag, and K.L. Rudolph Hepatocellular carcinoma: epidemiology and molecular carcinogenesis Gastroenterology 132 2007 2557 2576
3. H.B. El-Serag Hepatocellular carcinoma N Engl J Med 365 2011 1118 1127
4. C.J. Liu, and J.H. Kao Hepatitis B virus-related hepatocellular carcinoma: epidemiology and pathogenic role of viral factors J Chin Med Assoc 70 2007 141 145
5. M. Sherman, and J.M. Llovet Smoking, hepatitis B virus infection, and development of hepatocellular carcinoma J Natl Cancer Inst 103 2011 1642 1643
6. Y.F. Liaw, and C.M. Chu Hepatitis B virus infection Lancet 373 2009 582 592
7. C.J. Chen, and H.I. Yang Natural history of chronic hepatitis B REVEALed J Gastroenterol Hepatol 26 2011 628 638
8. C.J. Chen, H.I. Yang, and J. Su et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level JAMA 295 2006 65 73
9. J.C. Wu, Y.H. Huang, and G.Y. Chau et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma J Hepatol 51 2009 890 897
10. Y.F. Liaw Antiviral therapy of chronic hepatitis B: opportunities and challenges in Asia J Hepatol 51 2009 403 410
11. M.F. Yuen, and C.L. Lai Treatment of chronic hepatitis B: evolution over two decades J Gastroenterol Hepatol 26 Suppl 1 2011 138 143
12. Y.F. Liaw, J.J. Sung, and W.C. Chow et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease N Engl J Med 351 2004 1521 1531
13. Y.F. Liaw Impact of hepatitis B therapy on the long-term outcome of liver disease Liver Int 31 Suppl 1 2011 117 121
14. T.T. Chang, Y.F. Liaw, and S.S. Wu et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B Hepatology 52 2010 886 893
15. P. Marcellin, E. Gane, and M. Buti et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study Lancet 381 2013 468 475
16. C.L. Lai, and M.F. Yuen Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy Hepatology 57 2013 399 408
17. M. Sherman Does hepatitis B treatment reduce the incidence of hepatocellular carcinoma? Hepatology 58 2013 18 20
18. C.Y. Wu, Y.J. Chen, and H.J. Ho et al. Association between nucleos(t)ide analogues and risk of hepatitis B virus-related hepatocellula carcinoma recurrence following liver resection JAMA 308 2012 1906 1914
19. J.J. Sung, K.K. Tsoi, and V.W. Wong et al. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma Aliment Pharmacol Ther 28 2008 1067 1077
20. G.V. Papatheodoridis, P. Lampertico, and S. Manolakopoulos et al. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review J Hepatol 53 2010 348 356
21. J.Y. Cho, Y.H. Paik, and W. Sohn et al. Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease Gut 2014 Mar 10 Epub ahead of print
22. G.A. Niro, A.M. Ippolito, and R. Fontana et al. Long-term outcome of hepatitis B virus-related chronic hepatitis under protracted nucleos(t)ide analogues J Viral Hepatol 20 2013 502 507
23. C.Y. Wu, M.S. Wu, and K.N. Kuo et al. Effective reduction of gastric cancer risk with regular use of nonsteroidal anti-inflammatory drugs in Helicobacter pylori-infected patients J Clin Oncol 28 2010 2952 2957
24. C.Y. Wu, K.N. Kuo, and M.S. Wu et al. Early Helicobacter pylori eradication decreases risk of gastric cancer in patients with peptic ulcer disease Gastroenterology 137 2009 1641 1648 e1-e2
25. C.Y. Wu, F.K. Chan, and M.S. Wu et al. Histamine 2-receptor antagonists are an alternative to proton pump inhibitor in patients receiving clopidogrel Gastroenterology 139 2010 1165 1171
26. C.L. Cheng, Y.H. Kao, and S.J. Lin et al. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan Pharmacoepidemiol Drug Saf 20 2011 236 242
27. R.H. Dehejia, and S. Wahba Propensity score-matching methods for nonexperimental causal studies Rev Econ Stat 84 2002 151 161
28. R.L. Prentice, J.D. Kalbfleisch, and A.V. Peterson Jr. et al. The analysis of failure times in the presence of competing risks Biometrics 34 1978 541 554
29. R.J. Gray A class of K-sample tests for comparing the cumulative incidence of a competing risk Ann Stat 16 1988 1141 1154
30. D.Y. Lin, B.M. Psaty, and R.A. Kronmal Assessing the sensitivity of regression results to unmeasured confounders in observational studies Biometrics 54 1998 948 963
31. D.G. Altman, and P.K. Andersen Calculating the number needed to treat for trials where the outcome is time to an event BMJ 319 1999 1492 1495
32. G.V. Papatheodoridis, S. Manolakopoulos, and G. Touloumi et al. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study Gut 60 2011 1109 1116
33. A. Matsumoto, E. Tanaka, and A. Rokuhara et al. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: a multicenter retrospective study of 2795 patients Hepatol Res 32 2005 173 184
34. J.R. Eun, H.J. Lee, and S.H. Lee et al. The effect of lamivudine and adefovir dipivoxil on preventing hepatocellular carcinoma in hepatitis B virus-related liver cirrhosis Hepatology 46 2007 664A 665A
35. H.P. Chen, J.J. Shieh, and C.C. Chang et al. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies Gut 62 2012 606 615
36. H.B. El-Serag, T. Tran, and J.E. Everhart Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma Gastroenterology 126 2004 460 468
37. J.A. Davila, R.O. Morgan, and Y. Shaib et al. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study Gut 54 2005 533 539
38. V.W. Wong, S.L. Chan, and F. Mo et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers J Clin Oncol 28 2010 1660 1665
39. H.I. Yang, M. Sherman, and J. Su et al. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection J Clin Oncol 28 2010 2437 2444
40. H.I. Yang, M.F. Yuen, and H.L. Chan et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score Lancet Oncol 12 2011 568 574